What AbbVie’s Recent Performance Tells You

AbbVie (ABBV) has drawn investor attention after a mixed recent run in the stock. The share price is around $208.50, and performance has differed sharply between the past month and the past 3 months.

Over the past month, AbbVie is up about 1%, while the stock is down roughly 8% over the past 3 months and down about 9% year to date. Even with that pullback, the 1 year total return is about 21%, with 3 year and 5 year total returns of roughly 62% and 117% respectively.

Alongside the share performance, AbbVie reports annual revenue of about $62.8b and net income of roughly $3.6b. This points to a sizeable research based biopharmaceutical business across immunology, oncology, neuroscience, aesthetics, eye care and gastroenterology.

For context, AbbVie’s share price has slipped over the past 3 months but still sits well above its level a year ago. The recent pullback has tempered what had been strong longer term total shareholder returns. The recent decline in the 90 day share price return of 8.35% contrasts with a 21.33% 1 year total shareholder return, which suggests momentum has cooled in the short term even as longer term holders have still seen solid gains.

If this kind of mixed short term picture has you thinking about where else growth or resilience might be emerging in healthcare, it can be useful to widen your search to other companies using a focused screener such as 33 healthcare AI stocks

So with AbbVie trading near $208.50 after short term weakness but solid multi year total returns, and with analysts indicating a sizable discount to their price targets, is there still a buying opportunity here or is future growth already priced in?

Most Popular Narrative: 16.4% Undervalued

AbbVie’s most followed narrative pegs fair value around $249, which sits meaningfully above the recent $208.50 share price and puts the focus on how its core drugs and pipeline could support that gap.

AbbVie's diversified and expanding late-stage and early-stage pipeline, coupled with consistent business development activity (e.g., Capstan in vivo CAR-T, Gubra amylin analog for obesity, next-gen siRNA platforms), positions the company to capitalize on the increasing adoption of biologics and specialty pharmaceuticals, which can reinforce premium pricing and protect net margins.

Curious what justifies a higher fair value than today’s price? The narrative leans heavily on compounding revenue, much fatter margins, and a richer earnings multiple tied to that pipeline.

Result: Fair Value of $249 (UNDERVALUED)

However, this hinges on key risks, including competition eroding immunology pricing power and higher R&D or deal spending weighing on margins if new therapies disappoint.

Another Way To Look At AbbVie’s Valuation

The headline narrative says AbbVie is trading at a meaningful discount to fair value, yet its current P/E of 102.5x is far higher than the US Biotechs industry average of 17.7x, a peer average of 21.1x, and even the 36.9x fair ratio our model suggests the market could move toward.

That gap points to real valuation risk if sentiment or earnings expectations cool. The key question for you is whether AbbVie’s pipeline and margins can grow into that premium, or if the share price eventually drifts closer to those lower multiples.

Next Steps

If this mix of opportunities and concerns feels finely balanced, it is worth reviewing the underlying figures yourself and acting while the picture is still fresh in mind. To weigh both sides clearly, start with the 3 key rewards and 5 important warning signs.

Looking for more investment ideas?

If AbbVie has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not the one hearing about the next opportunity late.

• Target dependable income by reviewing 14 dividend fortresses that focus on higher yielding opportunities with robust underlying businesses.
• Search for potential value opportunities with 46 high quality undervalued stocks that combine quality fundamentals with prices that screens suggest may sit below estimated worth.
• Strengthen your core holdings by scanning solid balance sheet and fundamentals stocks screener (46 results) that prioritize financial resilience and support through different market conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.